Sand Mountain Sam is an opossum that predicts the weather around Feb. 2 every year, this year he did not see his shadow, which means there will be an early spring! Many people may be more familiar ...

SC upholds Dalit scholars’ right to compensation for loss of research data Uke and Das, both members of Scheduled Caste communities and PhD holders from the Jawaharlal Nehru University ...

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Scholar Rock is asking the U.S. Food and Drug Administration (FDA) to approve apitegromab, its experimental add-on therapy designed to boost motor function in people with spinal muscular atrophy (SMA) ...

The last time I wrote about Scholar Rock (NASDAQ:SRRK) it was with respect to a Seeking Alpha article entitled as "Scholar Rock: SMA Program Strides Forward With Positive Clinical Data".

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...

Scholar Rock Trading Up 0.5 % SRRK stock opened at $42.56 on Thursday. The firm has a fifty day moving average price of $41.94 and a 200 day moving average price of $24.97. Scholar Rock Holding Co ...

(RTTNews) - Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, Wednesday announced the appointment ...

This page features the latest news about the Scholar Rock stock. Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious ...